First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy

Files
main.pdf (182.56 KB)
If you need an accessible version of this item, please submit a remediation request.
Date
2022
Authors
VandenDriessche, Thierry
Pipe, Steven W.
Pierce, Glenn F.
Kaczmarek, Radoslaw
Language
American English
Embargo Lift Date
Department
Pediatrics, School of Medicine
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Elsevier
Abstract
Description
Keywords
Drug approval, Genetic therapy, Hemophilia A
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
VandenDriessche T, Pipe SW, Pierce GF, Kaczmarek R. First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy. Mol Ther. 2022;30(11):3335-3336. doi:10.1016/j.ymthe.2022.09.020
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Molecular Therapy
Rights
Publisher Policy
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Permanent Link
https://hdl.handle.net/1805/40073
DOI
https://doi.org/10.1016/j.ymthe.2022.09.020
Version
Final published version
Full Text Available at
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637642/
This item is under embargo {{howLong}}
Collections
Open Access Policy Articles
Department of Pediatrics Works